Hot Products
| Catalog No. | Information |
| CFN99170 | Astragaloside Astragaloside may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats. Astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-κB, finally the relative activity of caspase-3 activated. Astragaloside has several pharmacological actions on cardiovascular system, including positive inotropic, anti-arrhythmia and anti-oxidant activities; it also has anti-apoptotic activity, which may contribute to the improvement of clinical outcomes in treating myocarditis with pharmaceutics of Astragalus membranaceus. |
| CFN99172 | Astragaloside I Astragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway. |
| CFN99173 | Astragaloside II Astragaloside II is a potent autophagy inhibitor and multidrug resistance (MDR) reversal agent, which restores chemosensitivity of anticancer agent cisplatin and enhances tumor cell death. It has immunomodulating activity, can trigger T cell activation through regulation of CD45 protein tyrosine phosphatase activity, it induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways. |
| CFN99174 | Astragaloside III Astragaloside III has anti-gastric ulcer effects, and exhibits strong growth-promoting effects in cultured GES-1 cells. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer. |
| CFN99171 | Astragaloside IV Astragaloside IV can protect the myocardium against ischemia/reperfusion injury, inhibit adenovirus replication and apoptosis in A549 cells in vitro, has anti-fibrotic effect against systemic sclerosis, and may be useful in ameliorating food-induced metabolic syndrome and membranous nephropathy. It suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. |
| CFN91686 | Astragenol Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research. |
| CFN90648 | Astrasieversianin VII Isoastragaloside II is an astragaloside, which is isolated from the hairy root culture of Astragalus membranaceus. |
| CFN92486 | Astringin Astringinin is a potent antiarrhythmic agent with cardioprotective activity in ischemic and ischemic-reperfused rat heart, the beneficial effects of astringinin in the ischemic and ischemic-reperfused hearts may be correlated with its antioxidant activity and upregulation of NO production. Astringinin can significantly attenuate proinflammatory responses and hepatic injury after trauma-hemorrhage, the salutary effects of astringinin administration on attenuation of hepatic injury following trauma-hemorrhage are likely due to reduction of pro-inflammatory mediator levels. |
| CFN97991 | Atalantoflavone Atalantoflavone shows urease inhibitory potential. It displays weak cytotoxic activity against the human Caucasian prostate adenocarcinoma cell line PC-3. |
| CFN99944 | Atractylenolide I Atractylenolide I, a TLR4-antagonizing agent, shows a wide spectrum of pharmacological activities such as anti-inflammatory, digestion promoting,significant antitumor, and antioxidant effects. It ameliorates sepsis syndrome,liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. |
